Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

Todd Neale

March 08, 2023

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

Todd Neale

April 08, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

Presentation ACC 2021

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Presenter: Ajay J. Kirtane

May 16, 2021

News Conference News ACC 2020

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

Todd Neale

March 30, 2020

News Conference News ACC 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Michael O'Riordan

April 01, 2019

Advertisement

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content